Please assess the completion status of the following clinical trial:

Trial Title: Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Synchronous or metachronous colorectal metastases~* Technically resectable liver metastases~  * Four or fewer metastases~ * No tumors in porta hepatis~ * Resection of no more than 70% of liver needed~* Medically suitable candidate for major liver resection~* FDG-PET scan without metastatic disease outside the liver~Exclusion Criteria:~* Near-obstructing or obstructing colon lesions in patients in whom combined resection is planned (as delay for preoperative chemotherapy would be medially impossible)~* Treatment with FOLFOX or cetuximab within 12 months~* Treatment with irinotecan within 12 months~* Abnormal liver function (ALT or AST \> 5x ULN, bilirubin \> 3x ULN)~* Body mass index \>/= 35 kg/m² (as the risk for steatohepatitis is increased)~* Renal insufficiency (Cr \> 2.5mg/dL)~* Interstitial lung disease (because cetuximab has been rarely associated with development of interstitial lung disease)~* ECOG performance score \>/= 3~* Patients unable to give informed consent~* Pregnant patient (as cetuximab is a Class C drug)~* Peripheral neuropathy \>/= grade II (as oxaliplatin causes neuropathy to worsen)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Wildtype (Type: EXPERIMENTAL): Neoadjuvant therapy~Week 1~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Weeks 2, 4, 6, 8 \*Cetuximab 250 mg/m\^2 IV weekly~Weeks 3, 5, 7~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~\*Cetuximab 250 mg/m\^2 IV weekly
- Arm 2 K-Ras 12/13 codon mutation (Type: EXPERIMENTAL): Neoadjuvant Therapy~Weeks 1, 3, 5~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* Bevacizumab 5 mg/kg IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Week 7~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* Bevacizumab 5 mg/kg IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Week 7, 15~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues